Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Aim: The objectives of the study were to determine whether thiazolidinedione (TZD) use is associated with an increased risk of fracture in men and women with type 2 diabetes mellitus and to compare the effects of pioglitazone and rosiglitazone. Materials and Methods: A research database of integrated pharmacy and medical claims was analysed using Cox models adjusted for age, gender, chronic obstructive pulmonary disease, asthma, osteoporosis, stroke, prior fracture and chronic disease score. Patients were followed for 540 days. Results: There was a 39% higher [adjusted hazard ratio (HR), 1.39; 95% confidence interval (CI), 1.32–1.46] incidence of fractures in men and women exposed to a TZD ( n = 69047; age = 56 ± 5 years; 59% men; 48% rosiglitazone) compared with that in control patients ( n = 75352; age = 56 ± 5 years; 51% men). Men treated with a TZD had a higher likelihood of fracture than control patients (adjusted HR rosiglitazone, 1.47; 95% CI, 1.38–1.56; adjusted HR pioglitazone, 1.43; 95% CI, 1.34–1.52). The HRs associated with pioglitazone (adjusted HR, 1.43; 95% CI, 1.34–1.52) and rosiglitazone (adjusted HR, 1.47; 95% CI, 1.38–1.56) were almost identical. TZD use was associated with a higher fracture risk in women aged above and below 50 years and in men aged above 50 years. Conclusions: Our findings add support to the growing literature that TZD treatment is associated with an increased risk of fractures in both men and women, that effects of rosiglitazone and pioglitazone are similar and that fracture risk is increased even in younger women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Self-citation
Cited by
Nonalcoholic Fatty Liver Disease: A Systematic Review
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,267
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527
Bone fragility in diabetes: novel concepts and clinical implications
Hofbauer, L. C., Busse, B., Eastell, R., Ferrari, S., Frost, M., Müller, R., Burden, A. M., Rivadeneira, F., Napoli, N., & Rauner, M. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00347-8 · Cited by 440
Kovacs, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 387
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
Metadata
- Authors
- Aubert, R. E., Herrera, V., Chen, W., Haffner, S. M., & Pendergrass, M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2010-06-24
- Volume
- 12
- Issue
- 8
- Pages
- 716-721
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2020030439
- Cited by
- 135
- References
- 4
- FWCI
- 8.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01225.x
- The paper
- Aubert, R. E., Herrera, V., Chen, W., Haffner, S. M., & Pendergrass, M. (2010). Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01225.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.